AETHLON MEDICAL INC - AEMD STOCK NEWS

Aethlon Medical (Nasdaq: AEMD) has published a preclinical study demonstrating the ability of its Hemopurifier® to remove extracellular vesicles (EVs) and microRNAs from renal perfusates following Controlled Oxygenated Rewarming of discarded donor kidneys. The study, published in bioRxiv on August 24, 2024, supports further research into using the Hemopurifier® as part of a machine perfusion circuit to assess its impact on retrieved kidney function.

The proof-of-concept study used four perfusates from discarded donor kidneys, confirming the removal of both small and larger size EVs and a significant reduction in microRNAs. This research could potentially address complications associated with extended criteria donor kidneys, which often result in poor graft function and acute rejection in recipients.

Aethlon Medical (AEMD) reported financial results for Q1 FY2025 ended June 30, 2024. Key highlights:

1. Received ethics approvals for Hemopurifier® trial in Australia for solid tumor patients not responding to anti-PD-1 antibodies.

2. Expects to open patient enrollment in October 2024.

3. Achieved 24% reduction in Q1 operating expenses vs. Q1 FY2024.

4. Cash balance of $9.1 million as of June 30, 2024.

5. Net loss decreased to $2.6 million in Q1 FY2025 from $3.3 million in Q1 FY2024.

6. Exploring Hemopurifier use for viral infections.

7. COVID-19 trial in India remains open.

Aethlon Medical, Inc. (NASDAQ: AEMD) has received ethics approval for a clinical trial of its Hemopurifier® device in patients with solid tumors. The trial, to be conducted at Pindara Private Hospital in Australia, will evaluate the safety and feasibility of the Hemopurifier® in patients with stable or progressive disease during anti-PD-1 monotherapy treatment.

The Hemopurifier® is designed to remove harmful exosomes from biological fluids, which may improve therapeutic response rates to anti-PD-1 antibodies. The device has shown promise in preclinical studies for reducing exosomes in cancer patient plasma samples.

This development comes as the solid tumor therapeutics market is projected to reach $885.44 Billion by 2033, with smaller companies making significant advancements in treatments alongside big pharma.

Aethlon Medical (NASDAQ: AEMD) has received full ethics approval from the Bellberry Human Research Ethics Committee for a clinical trial of its Hemopurifier® at Pindara Private Hospital in Queensland, Australia. The trial will study the safety, feasibility, and dosing of the Hemopurifier in patients with solid tumors not responding to anti-PD-1 antibodies like Keytruda® or Opdivo®. This is the second ethics approval for the oncology trial in Australia, following approval at Royal Adelaide Hospital in June.

The trial aims to enroll 9-18 patients and will focus on safety as the primary endpoint. It will also explore the Hemopurifier's ability to reduce extracellular vesicles (EVs) in cancer patients' blood, which may improve response rates to anti-PD-1 therapies. The study results are expected to inform the design of a future Premarket Approval (PMA) study.

Aethlon Medical (Nasdaq: AEMD), a medical therapeutic company developing products for cancer and infectious diseases, has announced its fiscal first quarter financial results release and conference call for August 14, 2024. The company will issue financial results for the quarter ended June 30, 2024, at 4:15 p.m. ET, followed by a conference call at 4:30 p.m. ET. Management will review financial results and recent corporate developments, with a subsequent Q&A session. Interested parties can register online or dial in directly. A replay will be available until September 14, 2024, accessible via Aethlon's website or by phone.

Aethlon Medical (Nasdaq: AEMD) announced financial results for the fiscal year ending March 31, 2024, and provided a corporate update. The company continues the clinical development of its Hemopurifier® for cancer and infectious diseases, receiving ethics approval for a clinical trial in Australia. Financially, Aethlon reported a net loss of $12.2 million, a slight increase from the previous year's $12 million. Operating expenses rose marginally to $12.6 million from $12.5 million, driven by increased payroll costs. The current cash balance stands at $9.1 million. Efforts are ongoing to secure approvals for additional trial sites in Australia and India, with patient enrollment expected by late 2024.

Aethlon Medical (Nasdaq: AEMD) will release its fiscal year-end financial results on June 27, 2024, at 4:15 p.m. ET. The company focuses on developing therapeutic products for cancer and serious infectious diseases.

Management will host a conference call the same day at 4:30 p.m. ET to discuss the financial results and recent corporate developments. The call will include a Q&A session.

Participants can register for the call at https://dpregister.com/sreg/10190237/fce977aef1, where they will receive dial-in numbers. Those without internet access can dial in toll-free at 1-844-836-8741 or internationally at 1-412-317-5442.

A replay of the call will be available until July 27, 2024, via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international), using replay conference ID 6876352.

Investorideas.com has released an industry snapshot on the future treatment of solid cancer tumors, highlighting Aethlon Medical's (NASDAQ: AEMD) advancements. Aethlon announced the Human Research Ethics Committee's approval for a clinical trial of its Hemopurifier in cancer patients with stable or progressive disease during anti-PD-1 therapy, valid until June 2027. This trial aims to improve responses to treatments like Keytruda and Opdivo by removing extracellular vesicles from the bloodstream. The Hemopurifier has shown promise in preclinical studies, reducing exosomes in cancer patient samples. The trial, led by Prof. Michael Brown in Adelaide, Australia, will evaluate safety and treatment efficacy over two months. The market for solid tumor therapeutics is projected to grow from USD 222.71 billion in 2023 to USD 885.44 billion within ten years, driven by increased R&D investments. Key developments include AbbVie's acquisition of ImmunoGen and significant advancements in their antibody-drug conjugate platform.

Aethlon Medical received ethics approval from the Human Research Ethics Committee of the Central Adelaide Local Health Network for its Hemopurifier® cancer trial. The trial, focusing on safety, feasibility, and dose-finding, targets cancer patients with solid tumors unresponsive to anti-PD-1 antibodies. Conducted by Prof. Michael Brown's team in Adelaide, Australia, the study aims to reduce extracellular vesicles to improve therapeutic responses. The approval is valid until June 13, 2027. The primary endpoint is safety, with patient enrollment following a two-month PD-1 antibody monotherapy period. Aethlon plans to seek additional approvals in Australia and India.